CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 CANDOR STUDY BY NUMBER OF PRIOR LINES OFTHERAPY AND PRIOR THERAPIES H. Quach; A. Nooka; O. Samoylova; C.P. Venner; T. Facon; A. Spencer; S.Z. Usmani; K. Weisel; M. Mateos; K. Kim; S. Grosicki; K. Suzuki; S. Delimpasi; M. Obreja; A. Zahlten-Kumeli;

POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE AFTER 1 PRIOR LINE OF THERAPY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF OPTIMMISM BY AGE, PRIOR TRANSPLANT, AND HIGH-RISK CYTOGENETICS M. Dimopoulos; K. Weisel; P. Moreau; L.D.A. Jr; D. White; J.S. Miguel; P. Sonneveld; M. Engelhardt; M. Jenner; A. Corso; J. Dürig; M. Pavic; M. Salomo; E. Casal; R. Jiang; T. Nguyen; T. Peluso; P. Richardson;

EFFICACY AND SAFETY OF CARFILZOMIB, DEXAMETHASONE, DARATUMUMAB TWICE-WEEKLY AT 56 MG/M2 AND ONCE-WEEKLY AT 70 MG/M2 IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: CROSS-STUDY COMPARISON OF CANDOR AND MMY1001 X. Leleu; M. Beksac; T. Chou; M.A. Dimopoulos; S. Yoon; H.M. Prince; A. Chari; A. Oriol; D.S.D. Siegel; M. Khurana; M. Qi; M. Obreja; L. Pour; T. Shelekhova;